ONCO Onconetix, Inc.

NEUTRAL Impact: 3/10 8-K
Horizon weeks Filed Apr 24, 2026 Processed 1mo ago SEC 0001213900-26-047577
8-K context-dependent: Items 5.02
Latest settled — T+20d
ONCO ▼ -83.02% at T+20d
NEUTRAL call ✗ call lost -83.02% · α vs SPY -87.98% · entry $7.42 → $1.26
Next anchor: T+60d in 6w
Currently $0.9469 · -87.24% from $7.42 entry
Entry anchored
Apr 24, 03:49 PM ET
via Databento tick
T+1d
+3.52%
call +3.52% · α +4.00%
$7.68
settled 6w ago
T+5d
-12.83%
call -12.83% · α -13.23%
$6.47
settled 6w ago
T+20d
-83.02%
call -83.02% · α -87.98%
$1.26
settled 19d ago
T+60d
call — · α —
in 6w

Price Chart

Loading chart...

Executive Summary

Onconetix, Inc. announced the resignation of directors Andrew Oakley and Thomas Meier, the appointment of Sammy Dorf as Chairman of the Board with $20,000 annual compensation, and the election of Josh Epstein to the Board and its committees. The changes reflect a board refreshment with no disclosed disagreements or operational issues.

Actionable Insight

Monitor upcoming proxy filings for full director compensation details and any further governance changes. The addition of Epstein with M&A and capital markets expertise may signal strategic development plans, though no immediate financial impact is expected.

Key Facts

  • Andrew Oakley and Thomas Meier resigned from the Board of Directors effective April 20, 2026, with no disagreements reported.
  • Sammy Dorf was appointed Chairman of the Board effective April 23, 2026, and will receive $20,000 per year in compensation.
  • Josh Epstein was elected to the Board and named chair of the Nominating and Corporate Governance Committee, bringing extensive cross-industry executive and legal experience.
  • Epstein's compensation will be consistent with other non-employee directors.
  • Oakley also stepped down as Chairman and from the Audit, Compensation, and Nominating Committees; Meier resigned from the Compensation Committee.

Financial Impact

Minimal; $20,000 annual increase in director compensation

compensationgovernance

Risk Factors

  • Potential loss of institutional investor confidence if board stability is perceived as weak
  • Integration risk of new directors into key committees

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-047577
Document: 0001213900-26-047577-index-headers.html0001213900-26-047577
Document: 0001213900-26-047577-index.html0001213900-26-047577
Document: 0001213900-26-047577.txt0001213900-26-047577
12 reports for ONCO
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+20▲ +72.89%May 8, 2026
Filters
Rows
Reports for ONCO — sortable, filterable
Type Now
May 19, 2026
21d ago
Press Release
BEARISH ★ 5/10
$1.18 $1.20▼ −1.70%▲ +0.54%$0.9469 (+19.75%)
May 13, 2026
27d ago
Press Release
NEUTRAL ★ 3/10
$3.87 $1.10▼ −71.58%▼ −71.44%$0.9469 (−75.53%)
May 8, 2026
4w ago
EFFECT
BEARISH ★ 7/10
$3.80 $3.74▲ +1.58%▲ +1.79%$0.9469 (+75.08%)
May 7, 2026
4w ago
S-1/A
NEUTRAL ★ 2/10
$4.04 $3.90▼ −3.47%▼ −5.76%$0.9469 (−76.56%)
Apr 24, 2026
6w ago
8-K
NEUTRAL ★ 3/10
$7.42 $6.47▼ −12.83%▼ −13.23%$0.9469 (−87.24%)
Apr 16, 2026
7w ago
3
NEUTRAL ★ 2/10
$7.60 $6.66▼ −12.32%▼ −13.30%$0.9469 (−87.54%)
Apr 9, 2026
8w ago
PRESS-RELEASE / 425
BULLISH ★ 6/10
$12.20 $7.60▼ −37.70%▼ −40.89%$0.9469 (−92.24%)
Apr 2, 2026
9w ago
PRESS-RELEASE / 425
MIXED ★ 6/10
$15.20 $10.90▼ −28.29%▼ −31.91%$0.9469 (−93.77%)
Mar 31, 2026
10w ago
425
BULLISH ★ 7/10
$14.90 $11.30▼ −24.16%▼ −28.11%$0.9469 (−93.64%)
Mar 31, 2026
10w ago
Press Release
NEUTRAL ★ 4/10
$14.90 $11.30▼ −24.16%▼ −28.11%$0.9469 (−93.64%)
Showing 10 of 12

US Market Status

Market Closed — Opens Thu (10h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access